FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

CGMP Violations at Italian Drug Plan

In an untitled letter, FDA says Milan, Italy-based Industria Farmaceutica is manufacturing drugs with CGMP violations.

latest-news-card-1
Human Drugs

FDA Extends Treosulfan NDA Review by 3 Months

Medexus Pharmaceuticals says FDA has extended the review of its Medac licensors resubmitted NDA for treosulfan and its use in allogeneic hematopoietic...

latest-news-card-1
Human Drugs

SSM St. Clare Health Gets FDA-483

FDA issues SSM St. Clare Health Center a 10-observation Form FDA-483 for GMP deficiencies found during an inspection at an outsourcing facility in Fen...

latest-news-card-1
Human Drugs

Guide on Oncology Multiregional Clinical Trials

FDA posts a draft guidance entitled Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs (CDP).

latest-news-card-1
Federal Register

3 De Novo Device Classifications

Federal Register notices: FDA classifies three devices into Class 2 based on de novo classification requests Saladax Biomedicals MyCare Psychiatry Cl...

Animal Drugs

CVM Draft Guide on CMC Technical Section

FDA releases a CVM draft guidance entitled Chemistry, Manufacturing, and Controls (CMC) Technical Section Filing Strategies.

latest-news-card-1
Human Drugs

Apple Watch Cleared for Assessing Sleep Apnea

FDA clears an Apple 510(k) for its Apple Watch to be used as an over-the-counter device for assessing the risk of sleep apnea.

latest-news-card-1
Human Drugs

Boehringer Ingelheim Plans Pulmonatry Fibrosis NDA

Boehringer Ingelheim plans an NDA for nerandomilast for treating idiopathic pulmonary fibrosis (IPF) after reporting that its Phase 3 FIBRONEER-IPF st...

latest-news-card-1
Medical Devices

Fresenius Recalls Ivenix Pump Administration Sets

Fresenius Kabi recalls (Class 1) one lot of the Ivenix Large Volume Pump primary administration sets after documenting a manufacturing defect.

latest-news-card-1
Human Drugs

Clinical Hold Lifted on Zentalis Azenosertib

FDA removes a partial clinical hold on Zentalis Pharmaceuticals azenosertib studies into the drugs use against solid tumors and two cancer types.